Abbott Laboratories $ABT is Trexquant Investment LP's 9th Largest Position

Key Points

• Trexquant Investment LP reduced its stake in Abbott Laboratories by selling 13,313 shares, bringing their total ownership to 390,305 shares, valued at approximately $51.77 million.
• Abbott Laboratories reported a quarterly EPS of $1.26, in line with analysts’ expectations, with revenue increasing by 7.4% compared to the previous year.
• The company recently declared a quarterly dividend of $0.59, representing an annual yield of 1.8% and a payout ratio of 29.57%.

Trexquant Investment LP trimmed its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 3.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 390,305 shares of the healthcare product maker's stock after selling 13,313 shares during the quarter. Abbott Laboratories comprises approximately 0.6% of Trexquant Investment LP's portfolio, making the stock its 9th largest holding. Trexquant Investment LP's holdings in Abbott Laboratories were worth $51,774,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of ABT. Kelly Financial Services LLC purchased a new stake in shares of Abbott Laboratories during the 1st quarter valued at approximately $216,000. Voleon Capital Management LP purchased a new stake in shares of Abbott Laboratories during the 4th quarter valued at approximately $273,000. Bank Pictet & Cie Europe AG raised its position in shares of Abbott Laboratories by 1.9% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker's stock valued at $17,274,000 after buying an additional 2,774 shares during the period. Edge Financial Advisors LLC raised its position in shares of Abbott Laboratories by 3.3% during the 1st quarter. Edge Financial Advisors LLC now owns 2,530 shares of the healthcare product maker's stock valued at $336,000 after buying an additional 81 shares during the period. Finally, Ameriprise Financial Inc. raised its position in shares of Abbott Laboratories by 6.5% during the 4th quarter. Ameriprise Financial Inc. now owns 12,865,656 shares of the healthcare product maker's stock valued at $1,451,032,000 after buying an additional 781,264 shares during the period. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Stock Up 0.9%

Shares of NYSE:ABT traded up $1.22 during trading on Monday, hitting $132.59. The company's stock had a trading volume of 4,430,637 shares, compared to its average volume of 5,346,421. The business has a 50 day moving average price of $130.99 and a two-hundred day moving average price of $131.34. The company has a market capitalization of $230.76 billion, a PE ratio of 16.61, a P/E/G ratio of 2.52 and a beta of 0.69. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting the consensus estimate of $1.26. The business had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The company's quarterly revenue was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, research analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th were paid a $0.59 dividend. The ex-dividend date was Tuesday, July 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. Abbott Laboratories's payout ratio is 29.57%.

Analysts Set New Price Targets

Several research firms have recently commented on ABT. William Blair raised shares of Abbott Laboratories to a "strong-buy" rating in a research report on Thursday, July 17th. Jefferies Financial Group raised shares of Abbott Laboratories from a "hold" rating to a "buy" rating and lifted their price target for the company from $143.00 to $145.00 in a research report on Friday, July 18th. Royal Bank Of Canada boosted their target price on Abbott Laboratories from $145.00 to $147.00 and gave the company an "outperform" rating in a research report on Tuesday, July 15th. Evercore ISI boosted their target price on Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a research report on Tuesday, July 8th. Finally, Leerink Partners started coverage on Abbott Laboratories in a research report on Monday, June 16th. They issued a "market perform" rating and a $143.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $144.47.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the business's stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer owned 51,003 shares in the company, valued at $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.46% of the stock is currently owned by company insiders.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.